Pien Tze Huang, the market value of "Moutai in Medicine" has shrunk by 140 billion, and no one wants 760 yuan a pill
Pien Tze Huang, once known as "Moutai in medicine", once had a price of 1,000 yuan, queued up to limit purchases, and repeatedly ran out of stock in the frenzied hype that caused a sensation in the pharmaceutical market in 2021, and its market value once soared to nearly 300 billion yuan. However, with the passage of time, the crazy hype phenomenon gradually subsided, and now, the official price of a Pien Tze Huang lozenge with only 3 grams is only 760 yuan. By October 2023, the company's market value has evaporated by more than 140 billion yuan, which is equivalent to the market value of Tsingtao Beer.
The origin of Pien Tze Huang can be traced back to the end of the Ming Dynasty, according to legend, a court physician during his exile in Zhangzhou, Fujian, refined a medicine tablet that can clear heat and detoxify, and it needs to be cut into thin slices when used, so it is called "Pien Tze Huang". In 1956, Zhangzhou Pharmaceutical Factory incorporated it into production and became the company's trump card. In 2003, the pharmaceutical factory was renamed Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. and listed.
In 2021, Pien Tze Huang set off a boom in the market. At one time, it was priced at "3 grams per capsule, one capsule per box, and 1600 per box", and it was still in short supply. On online e-commerce platforms, Pien Tze Huang's orders need to be booked in advance and then wait 2-4 weeks to buy them. At its peak, "1,600 yuan per pill" became a hot topic, with nearly 20 million views.
Pien Tze Huang is favored by the business community and is known as the miracle medicine of "eating after drinking Moutai, which can relieve hangover and protect the liver". A chairman of Shenzhen Linyuan even said in public that in the seventies and eighties of the last century, Pien Tze Huang's ** was twice that of Moutai, and now Moutai is sold for 1,500 yuan, and Pien Tze Huang can rise even higher. At the same time, the share price of Zhangzhou Pharmaceutical Factory also rose 79 in the second half of the year41% record, which soared to 491 at one point88 yuan, with a market value of more than 260 billion.
However, medical expert Shi Lichen believes that this is obviously hype, which has brought harm to the entire pharmaceutical industry. **Liu Chunsheng, an associate professor at the University of Finance and Economics, pointed out that when Pien Tze Huang is in short supply and hype is pushed, a "herd effect" will be formed.
However, at the beginning of 2023, Pien Tze Huang's frenzied hype is completely over. Originally, the price of 3 grams per grain and 1600 yuan per grain no longer exists, and the official channel price is only 760 yuan. According to industry sources, since September last year, Pien Tze Huang's **all the way**, has fallen by nearly 40% during the year, and the lowest price has even fallen below the official guide price.
It is understood that at the highest time, a box of Pien Tze Huang could even be sold for more than 10,000 yuan. But with the end of the hype, "it is very difficult to think of the original price of 7600 yuan box ** now." ”
In fact, the hype of ** drugs often only benefits a few shareholders and scalpers, while the takers and the market are hurt. This phenomenon is not unique. In 2021, more than 20 anti-aging and tonic biotechnology companies gathered together and set 8 daily limits in 10 trading days. However, after the State Administration for Market Regulation intervened to call a halt, the market value of these sectors quickly fell back and almost halved.
On the other hand, the mitochondrial activator Schginer has also attracted much attention in recent years, and has been proven through clinical studies to intervene in age-related aging symptoms and prolong the lifespan of mammals. Although the price is around 1,000 yuan and it has entered the consumer market through channels such as JD.com, some people question whether there is a "IQ tax", similar to Pien Tze Huang.
In recent years, the pricing of drugs in the field of big health seems to be becoming more and more ambiguous, with both Dong'e Ejiao at 6,000 yuan per kilogram and rare disease drugs at 14 million per shot. They, like Pien Tze Huang and Shi Jiner, seem to be just one part of the numbers game in the pharmaceutical market.
In short, speculation on high drugs** is a double-edged sword, which may bring economic benefits in the short term, but in the long run, scientific research strength and reputation are the key to the sustainable development of enterprises. Hype can end up having a negative impact on the growth of a business.